ALKS Q1 2022 Earnings — Alkermes plc Revenue & Financial Results | Market Cap Arena

ALKSAlkermes plc

$5B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$279M+10.8% YoY

Gross Profit

$223M80.2% margin

Operating Income

-$27M-9.5% margin

Net Income

-$36M-12.9% margin

EPS (Diluted)

$-0.22

QoQ Revenue Growth

-14.2%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$14M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$902M

Stockholders' Equity

$1.1B

Cash & Equivalents

$283M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$279M	$251M	+10.8%
Gross Profit	$223M	$210M	+6.2%
Operating Income	-$27M	-$16M	-61.8%
Net Income	-$36M	-$22M	-60.2%

Revenue Segments

Product

$171M50%

Vivitrol

$85M25%

Aristada And Aristada Initio

$72M21%

L Y B A L V I

$14M4%